Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Sterile Formulation Comprising a Stable Phosphorothioate Oligonucleotide

a technology of phosphorothioate and oligonucleotide, which is applied in the direction of gene therapy, biochemistry apparatus and processes, pharmaceutical non-active ingredients, etc., can solve the problems of phosphorothioate stability problems, and phosphorothioate oligonucleotides are susceptible to desulfurization, so as to preserve the ability to inhibit irs-1 expression

Active Publication Date: 2018-08-09
GENE SIGNAL INT
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a composition that increases the stability of phosphorothioate oligonucleotides, which are modified to be resistant to degradation by nucleases. The composition includes a thiol group-containing agent that prevents degradation and a phosphate compound that stabilizes the structure of the oligonucleotides. The composition can also include a surfactant for various purposes such as improving dissolution and dispersability. In summary, the patent provides a way to protect and stabilize phosphorothioate oligonucleotides for research and therapeutic purposes.

Problems solved by technology

However, stability issues arise with phosphorothioate nucleotides in emulsions.
Indeed, phosphorothioate oligonucleotides are susceptible to desulfurization through the action of peroxide radicals generated from excipients present in the compositions.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sterile Formulation Comprising a Stable Phosphorothioate Oligonucleotide
  • Sterile Formulation Comprising a Stable Phosphorothioate Oligonucleotide

Examples

Experimental program
Comparison scheme
Effect test

example 1

ed Stability Study of GS-101 in Presence of Phosphate

[0399]The accelerated stability study of GS-101 is reported in this example. A composition containing 0.86 mg GS-101 / g emulsion was evaluated in 7 different formulations, comprising phosphate compounds and / or an antioxidant, such as an agent comprising a thiol group. These formulations were kept at different storage conditions, and the stability of GS-101 in the different formulations was evaluated by reversed-phase high-performance liquid chromatography (RP-HPLC).

[0400]Materials and Methods

[0401]Preparation of the Sterile Bulk Emulsion

[0402]8% w / w* of Miglyol 812™, 3.5% w / w* of Gelot 64® and 2% w / w* of cetyl alcohol were mixed in a beaker. The beaker was then placed onto a magnetic stirrer-heater adjusted at 70° C. The resulting oil phase was solubilized and homogenized under continuous stirring (300 rpm) at 70° C. for 10 minutes.

[0403]Parallelly, 0.05% w / w* or 0.1% w / w* of Carbopol® 980NF (depending on the formulation as describ...

example 2

Stability Study

[0431]A long-term stability study of GS-101 was initiated and is reported in this example. The emulsion containing 0.86 mg GS-101 / g emulsion was evaluated in 5 different formulations, comprising phosphate and / or an agent comprising a thiol group. These formulations were kept at different storage conditions, and the stability of GS-101 in the different formulations was evaluated by RP-HPLC, as described in Example 1.

[0432]Materials and Methods

[0433]Preparation of the GS-101 Sterile Emulsions

[0434]The GS-101 sterile emulsions were prepared similarly to the emulsions of Example 1. These emulsions can contain one or more of the following substances:[0435]0.1% w / w* or 0.25% w / w* of N-acetylcysteine (NAC);[0436]0.436% w / w* of Na2HPO4.12H2O and 0.039% w / w* of NaH2PO4.H2O (15 mM phosphate final in the total composition);[0437]0.086% w / w* of GS-101 having the sequence SEQ ID NO: 2 (5′-TCTCCGGAGGGCTCGCCATGCTGCT-3′). * percentages are given in w / w of the total composition.

[0438]...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperaturesaaaaaaaaaa
sizeaaaaaaaaaa
sizeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a composition comprising a phosphorothioate oligonucleotide and at least one fatty acid and / or at least one emulsifying agent, wherein said composition is sterile and wherein said composition comprises at least one agent comprising a thiol group and at least one phosphate compound, preferably said composition is an ophthalmic composition. The present invention also relates to a method for obtaining the same and to the therapeutic use thereof.

Description

FIELD OF INVENTION[0001]The present invention relates to the therapeutic use of oligonucleotides and aims at solving the problem of the stability of said oligonucleotides in a composition, in particular in a composition comprising at least one fatty acid and / or at least one emulsifying agent. More specifically, the present invention relates to a sterile composition comprising at least one fatty acid and / or at least one emulsifying agent, a phosphorothioate oligonucleotide, at least one agent containing a thiol group and at least one phosphate compound.BACKGROUND OF INVENTION[0002]Oligonucleotides are commonly used as laboratory tools and increasingly used as therapeutic agents. Oligonucleotides are characterized by their specificity, as they are able to recognize and bind to a specific target, for example through sequence complementarity by virtue of Watson-Crick base pairing. Antisense oligonucleotides, siRNAs and shRNAs, the most common oligonucleotides with therapeutic purposes, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/713A61K47/12A61K47/02A61K47/20A61K9/00A61K9/107A61K9/113C12N15/113
CPCA61K31/713A61K47/12A61K47/02A61K47/20C12N2310/11A61K9/107A61K9/113C12N15/1138C12N2310/315A61K9/0048C12N2320/51C12N15/113
Inventor VIAUD, ERICFERRY, ANTOINEMISSIAEN, CARLAVERCAMMEN, JO
Owner GENE SIGNAL INT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com